TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for CLOCK drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen (WT & Mutant) | CLOCK bHLH-PAS-A/B Domain Recombinant Protein. High purity (>95%), Endotoxin <1 EU/µg. Sequence Verified. Circadian-relevant mutant panel available. | View CLOCK Products |
| Heterodimer Partner (BMAL1) | BMAL1 (ARNTL) bHLH-PAS Domain Recombinant Protein. HEK293 Expressed. For PPI and heterodimerization assays. Sequence Verified. | View BMAL1 Products |
| Gene Delivery | CLOCK Promise-ORF / Lentivirus. Full-length ORF for stable cell lines and circadian reporter assays. | View CLOCK Products |
| Benchmark Ab | Anti-CLOCK Recombinant Rabbit mAb (ChIP-Grade). For target engagement, Western blot, and ICC validation. | View CLOCK Products |
| Validator | CLOCK siRNA Set. For knockdown verification and assay specificity control. | View CLOCK Products |
| Related Target: PER2 | PER2. Core negative feedback repressor of the CLOCK:BMAL1 complex; critical for circadian period modulation. | View PER2 Products |
| Related Target: CRY1 | CRY1. Cryptochrome repressor; direct repressor of CLOCK/BMAL1; essential for counter-screening. | View CRY1 Products |
| Paralog: NPAS2 | NPAS2. Brain-specific paralog with functional redundancy; critical for selectivity screening. | View NPAS2 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| CLOCK-BMAL1 PPI Disruption (Small molecule screening) | Purified bHLH-PAS domains with verified identity by LC-MS/MS. >95% purity by SDS-PAGE and SEC-HPLC. Suitable for SPR, FP, AlphaLISA. |
| Paralog Selectivity (CLOCK vs NPAS2) | Human NPAS2 PAS-B domain protein available for orthogonal counter-screening. Sequence verified. |
| Cell-based Circadian Reporter Assay | Full-length CLOCK Lentivirus (Promise-ORF) for stable integration into Bmal1-KO or PER2::Luc cell lines. |
| Intracellular Target Degradation (PROTAC) | Sequence-verified ORF plasmids and Lentivirus for PROTAC screening cell lines. |
| Lack of Controls | Research-grade recombinant antibody and validated siRNA included for target engagement confirmation. |
| False Positives in Screening | Sequence-verified siRNA for knockdown rescue and specificity validation. |
Live CLOCK R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for CLOCK-targeted therapeutics is intensifying, with major players shifting focus from traditional chronobiology and indirect circadian modulation (e.g., REV-ERB, ROR) to direct disruption of the CLOCK-BMAL1 transcriptional complex. First-generation small-molecule PPI inhibitors are advancing through preclinical validation, while Targeted Protein Degradation (PROTACs) emerge as a promising modality for oncology and metabolic syndrome. As CRY1/CRY2 stabilizers face specificity challenges, the next wave targets the upstream activator complex to enable tissue-specific circadian modulation without complete clock abolition. Key indications include metabolic syndrome, sleep-wake phase disorders, and cancer chronotherapy.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule (PPI Inhibitor/Disruptor) | Actogram Therapeutics, Eli Lilly (Synchronicity), Reset Therapeutics | Sleep disorders, Metabolic syndrome | CLOCK-BMAL1 heterodimer assay using purified PAS domains |
| Small Molecule (Allosteric) | Pharma circadian/metabolic divisions | Type 2 Diabetes, Cancer chronotherapy | Differential SPR against CLOCK vs NPAS2 PAS-B domains |
| PROTAC / Degrader | Academic Consortia, Preclinical Innovators | Oncology (e.g., Leukemia, chronotherapy) | Cell-based reporter assays with Lentivirus-stable lines |
| Peptide Mimetic | Novartis (circadian program) | Inflammation | PAS domain binding verification (High-purity recombinant fragments) |
| Gene Therapy / siRNA | Alnylam (research phase), Emerging metabolic genetic medicine platforms | NASH, Obesity, Liver Metabolism | CLOCK siRNA validation set for specificity and potency benchmarking |
Molecular Differentiation & Assay Strategy
Developing best-in-class CLOCK modulators requires rigorous differentiation. Key factors include affinity and binding kinetics (tunable partial inhibition needed vs complete blockade), subfamily selectivity (critical to avoid NPAS2 cross-reactivity), and mechanism validation via cell-based circadian reporter assays. TarMart provides full-length recombinant CLOCK and BMAL1 proteins with confirmed PAS domain integrity, enabling SPR/TR-FRET for PPI screening, and Lentivirus-based stable lines for functional rescue and degradation kinetics. Additionally, counter-screening panels including NPAS2, HIF-1α, and ARNT ensure selective targeting.
Related Targets (Cross-sell Strategy)
Based on the circadian pathway network, recommended associated targets for combined solutions: ARNTL (BMAL1) for heterodimer assays, NPAS2 for selectivity counter-screening, CRY1 for negative feedback control, and PER2 for period modulation studies. These targets are available as recombinant proteins, ORF clones, and antibodies via TarMart.